The histone deacetylase (HDAC) inhibitor vorinostat has received significant attention in recent years as an ‘epigenetic’ drug used to treat solid tumors. However, its mechanisms of action are not entirely understood, particularly with regard to its interaction with the aberrations in 3D nuclear structure that accompany neoplastic progression.

Reuse Permissions
  • Downloads
    pdf (0 B)

    Download count: 0


    Date Created
    Resource Type
  • Text
  • Collections this item is in
    • Digital object identifier: 10.1038/srep30593
    • Identifier Type
      International standard serial number
      Identifier Value

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Nandakumar, V., Hansen, N., Glenn, H. L., Han, J. H., Helland, S., Hernandez, K., . . . Meldrum, D. R. (2016). Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells. Scientific Reports, 6(1). doi:10.1038/srep30593

    Machine-readable links